| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: ≤10 μM (myosin II)[1]
JB002 targets myosin II, a motor protein essential for muscle contraction and various cellular processes. As a myosin II inhibitor with an IC50 of ≤10 µM, it blocks the motor activity of myosin II, thereby reducing contractile force. The compound exhibits good selectivity between cardiac and skeletal myosin isoforms. It is a valuable tool for studying myosin function, muscle physiology, and related pathological conditions such as muscle spasticity and hypertrophic cardiomyopathy. |
|---|---|
| ln Vitro |
JB002 has no discernible activity against non-muscle IIB, however it shows good selectivity between cardiac and skeletal myosins [1].
In vitro, JB002 demonstrates good selectivity between cardiac and skeletal myosin, with no detectable activity against nonmuscle IIB. As a myosin II inhibitor with an IC50 of ≤10 µM, it effectively inhibits myosin motor activity in biochemical assays. These in vitro characteristics support its use in studying myosin function and muscle physiology. The compound's selectivity profile makes it a useful tool for dissecting the roles of different myosin isoforms. |
| ln Vivo |
In vivo data for JB002 is not extensively reported in publicly available sources. As a myosin II inhibitor, the compound has potential applications in animal models of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy. By reducing contractile force, JB002 could provide insights into the pathophysiology of these conditions. However, specific published in vivo efficacy studies are not detailed in the current literature. JB002 is primarily used as a research tool for studying myosin function.
|
| Enzyme Assay |
The in vitro myosin II inhibition assay for JB002 uses purified myosin II and measures ATPase activity in the presence of varying concentrations of the compound. The ATPase activity is detected using colorimetric or luminescent methods, and IC50 values are calculated from dose-response curves. Selectivity profiling against different myosin isoforms (cardiac, skeletal, and nonmuscle IIB) is performed using similar assay formats to determine isoform specificity.
|
| Cell Assay |
Cellular assays for JB002 are conducted in muscle cells or relevant cell lines. Cells are treated with varying concentrations of JB002 (IC50 ≤10 µM). Cell contractility or myosin-dependent processes are assessed using appropriate functional assays. Cell viability and proliferation are measured using standard assays such as MTT to confirm that effects are not due to cytotoxicity. The compound's effects on myosin motor activity and cellular functions are evaluated.
|
| Animal Protocol |
In vivo studies for JB002 would typically involve animal models of muscle spasticity, chronic musculoskeletal pain, or hypertrophic cardiomyopathy. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring functional outcomes such as muscle contractility, pain responses, or cardiac function. However, specific published in vivo protocols for JB002 are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for JB002 is not extensively reported in publicly available sources. The compound has a molecular weight of 293.32 g/mol and a molecular formula of C18H15NO3. Storage conditions: protected from light, store at -80°C. As a small molecule myosin II inhibitor, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available in the current literature for this research compound.
|
| Toxicity/Toxicokinetics |
Toxicity data for JB002 is limited in publicly available sources. As with all research compounds, JB002 is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment. The compound's selectivity for cardiac and skeletal myosin over nonmuscle IIB suggests a favorable off-target profile.
|
| References | |
| Additional Infomation |
JB002 is a myosin II inhibitor with an IC50 of ≤10 µM that blocks the motor activity of myosin II, reducing contractile force. It exhibits good selectivity between cardiac and skeletal myosin, with no detectable activity against nonmuscle IIB. JB002 is used in research on muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy. It has a molecular formula of C18H15NO3 and a molecular weight of 293.32 g/mol.
|
| Molecular Formula |
C18H15NO3
|
|---|---|
| Molecular Weight |
293.316604852676
|
| Exact Mass |
293.105
|
| CAS # |
30408-07-2
|
| PubChem CID |
136744641
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
489
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2=C(C=CC=C2)C(O)=C(/C(=N/CC2=CC=CC=C2)/C)C1=O
|
| InChi Key |
RLBBDEFOYCZVDK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H15NO3/c1-12(19-11-13-7-3-2-4-8-13)16-17(20)14-9-5-6-10-15(14)22-18(16)21/h2-10,20H,11H2,1H3
|
| Chemical Name |
3-(N-benzyl-C-methylcarbonimidoyl)-4-hydroxychromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 31.25 mg/mL (106.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4092 mL | 17.0462 mL | 34.0925 mL | |
| 5 mM | 0.6818 mL | 3.4092 mL | 6.8185 mL | |
| 10 mM | 0.3409 mL | 1.7046 mL | 3.4092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
